Ревматоидный артрит: проблемы ремиссии и резистентности к терапии
https://doi.org/10.14412/1995-4484-2018-263-271
Аннотация
Ревматоидный артрит (РА) – иммуновоспалительное (аутоиммунное) ревматическое заболевание неизвестной этиологии, характеризующееся хроническим эрозивным артритом и системным поражением внутренних органов, приводящее к ранней инвалидности и сокращению продолжительности жизни пациентов. Несмотря на достигнутые успехи в лечении РА, связанные с разработкой новых лекарственных препаратов и совершенствованием стратегии лечения, позволяющие добиться ремиссии у многих пациентов, остается много теоретических и клинических проблем, касающихся как определения понятия «ремиссия», ее характеристики и типов, так и подходов к оптимальной тактике «симптоматической» и «патогенетической» лекарственной терапии на разных стадиях болезни, применение которой позволит быстро индуцировать состояние ремиссии и поддерживать ее в долгосрочной перспективе. Необходимы дальнейшие исследования, направленные на изучение природы гетерогенности патогенетических механизмов РА и подходов к ранней диагностике, совершенствование методов мониторинга активности заболевания, биомаркеров эффективности и резистентности к терапии и, наконец, разработку дифференцированной терапии, в том числе связанной с поиском новых «терапевтических» мишеней.
Об авторах
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Москва, Каширское шоссе, 34А;
кафедра ревматологии Института профессионального образования, 119991, Москва, ул. Трубецкая, 8, стр. 2
Ю. А. Олюнин
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Список литературы
1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelance]. Moscow: GEOTARMedia; 2008. P. 290-331 (In Russ.)].
2. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-48. doi: 10.1016/S0140-6736(17)31491-5
3. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37. doi: 10.1016/S0140-6736(17)31472-1
4. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15. doi: 10.1136/annrheumdis-2015-207524
5. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2016;76:948-59. doi: 10.1136/annrheumdis2016-210602
6. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis. 2016;75:16-22. doi: 10.1136/annrheumdis-2015-207526
7. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013;51(6):609-22 [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):609-22 (In Russ.)]. doi: 10.14412/1995-4484-2013-609-22
8. Ajeganova S, van Steenbergen HW, van Nies JA, et al. Diseasemodifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75(5):867- 73. doi: 10.1136/annrheumdis-2014-207080
9. Nagy G, van Vollenhoven RF. Sustained biologic-free and drugfree remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17:181. doi: 10.1186/s13075-015-0707
10. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75:1428-37. doi: 10.1136/annrheumdis-2016-209201
11. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86. doi: 10.1002/art.30129
12. Prevoo ML, van Gestel AM, van Thof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996;35:1101-5. doi: 10.1093/rheumatology/35.11.1101
13. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100-8.
14. Олюнин ЮА. Оценка активности заболевания при ревматоидном артрите: рекомендации и практика. Современная ревматология. 2014;8(2):15-20 [Olyunin YuA. Assessment of disease activity in rheumatoid arthritis: recommendations and practice. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(2):15-20. (In Russ.)]. doi: 10.14412/1996-7012- 2014-2-15-20
15. Gaujoux-Viala C, Mouterde G, Baillet A, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spain. 2012;79(2):149-55. doi: 10.1016/j.jbspin.2011.04.008
16. Smolen JS, Collaud Basset S, Boers M, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016;75(7):1268-71. doi: 10.1136/annrheumdis-2016-209429
17. Schoels M, Alasti F, Smolen JS, Aletaha D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther. 2017;19(1):155. doi: 10.1186/s13075-017-1346-5
18. Cheung PP, Gossec L, Mak A, March L. Reliability of joint count assessment in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:721-9. doi: 10.1016/j.semarthrit.2013.11.003
19. Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis. 2011;70:792-8. doi: 10.1136/ard.2010.134445
20. Ferreira RJO, Dougados M, Kirwan JR, et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017;56(9):1573-8. doi: 10.1093/rheumatology/kex211
21. Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 2012;71:1702-5. doi: 10.1136/annrheumdis-2012-201519
22. Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther. 2016;18:251. doi: 10.1186/s13075-016-1151-6
23. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9(10):249-62. doi: 10.1177/1759720X17720366
24. Einarsson JT, Geborek P, Saxne T, et al. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden. J Rheumatol. 2016;43(6):1017-23. doi: 10.3899/jrheum.150995
25. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960-77. doi: 10.1136/annrheumdis-2016-210715
26. Van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861-70. doi: 10.1136/annrheumdis-2012-203130
27. Hamann P, Holland R, Hyrich K, et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783-93. doi: 10.1002/acr.23016
28. Kuriya B, Xiong J, Boire G, et al; CATCH Investigators. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis – results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol. 2014;41(11):2161-6. doi: 10.3899/jrheum.140137
29. Einarsson JT, Willim M, Ernestam S, et al. Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. Rheumatology (Oxford). 2018 Mar 12. doi: 10.1093/rheumatology/key054
30. Cook MJ, Diffin J, Scire CA, et al. Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford). 2016;55(9):1601-9. doi: 10.1093/rheumatology/kew210
31. Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76(11):1906- 10. doi: 10.1136/annrheumdis-2017-211284
32. Michelsen B, Kristianslund EK, Hammer HB, et al. Discordance between tender and swollen joint count as well as patient’s and evaluator’s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2016;76:708-11. doi: 10.1136/annrheumdis-2016- 210283
33. Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018;57(5):835-43. doi: 10.1093/rheumatology/kex528
34. Vittecoq O, Richard L, Banse C, Lequerre T. The impact of smoking on rheumatoid arthritis outcomes. Join Bone Spine. 2018;85(2):135-8. doi: 10.1016/j.jbspin.2017.12.004
35. Juan S, Jiabi Z. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2018 Apr 7. doi: 10.1016/j.jbspin.2018.03.007
36. Betegnie AL, Gauchet A, Lehmann A, et al. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire. J Rheumatol. 2016;43(4):724-30. doi: 10.3899/jrheum.150414
37. Fautrel B, Den Broeder AA. De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol. 2015;29(4-5):550-65. doi: 10.1016/j.berh.2015.09.006
38. Verhoef LM, Tweehuysen L, Hulscher ME, et al. bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatol Ther. 2017;4(1):1- 24. doi: 10.1007/s40744-017-0055-5
39. Котовская МА, Никишина НЮ, Олюнин ЮА. Стратегия снижения дозы и отмены генно-инженерных биологических препаратов при ревматоидном артрите в стадии ремиссии. Научно-практическая ревматология. 2018;56(1):99-106 [Kotovskaya MA, Nikishina NYu, Olyunin YuA. Strategy for dose reduction and discontinuation of biological agents in rheumatoid arthritis remission. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):99-106 (In Russ.)]. doi: 10.14412/1995-4484-2018-99-106
40. Fautrel B. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. Joint Bone Spine. 2018. doi: 10.1016/j.jbspin.2018.02.002
41. Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018;77(4):515-22. doi: 10.1136/annrheumdis2017-212423
42. Van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recentonset rheumatoid arthritis. Ann Rheum Dis. 2009;68(6):914-21. doi: 10.1136/ard.2008.092254
43. Van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60(8):2262-71. doi: 10.1002/art.24661
44. Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73(6):1027-36. doi: 10.1136/annrheumdis-2013- 204882
45. Emery P, Hammoudeh M, FitzGerald O, et al. FRI0089 Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the prize study. Ann Rheum Dis. 2013;72:A399. doi: 10.1136/annrheumdis-2013-eular.1216
46. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19-26. doi: 10.1136/annrheumdis-2014-206106
47. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35- 43. doi: 10.1136/annrheumdis-2014-205752
48. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17-25. doi: 10.3109/14397595.2013.854079
49. Heimans L, Wevers-de Boer KV, Visser K, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. 2014;73:1356-61. doi: 10.1136/annrheumdis-2013-203243
50. Akdemir G, Heimans L, Bergstra SA, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2018;77(1):111-8. doi: 10.1136/annrheumdis-2017-211375
51. Emery P, Hammoudeh M, FitzGerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med. 2014;371(19):1781-92. doi: 10.1056/NEJMoa1316133
52. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389-95. doi: 10.1136/annrheumdis2013-204016
53. Van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424-32. doi: 10.1002/art.22525
54. Burgers LE, Allaart CF, Huizinga TWJ, et al. Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis Rheum. 2017;69(5):926-31. doi: 10.1002/art.40062
55. Насонов ЕЛ. Рекомендации EULAR по диагностике и лечению раннего артрита: 2016. Научно-практическая ревматология. 2017;55(2):138-50 [Nasonov EL. The 2016 EULAR guidelines for the diagnosis and treatment of early arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):138-50 (In Russ.)]. doi: 10.14412/1995- 4484-2017-138-150
56. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53(11):2110-8. doi: 10.1093/rheumatology/keu217
57. Алексеева ОГ. Ультразвуковое исследование суставов при ревматоидном артрите: патогенетическая обоснованность, возможности использования в диагностике, оценке эффективности терапии и прогнозировании исходов. Научно-практическая ревматология. 2018;56(1):82-92 [Alekseeva OG. Joint ultrasonography in rheumatoid arthritis: pathogenetic rationale, possible use in diagnosis, therapy efficiency evaluation, and outcome prediction. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):82-92 (In Russ.)]. doi: 10.14412/1995-4484-2018-82-92
58. Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804-14. doi: 10.1136/annrheumdis-2012-203158
59. Alivernini S, Peluso G, Fedele AL, et al. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Res Ther. 2016;18:39. doi: 10.1186/s13075-016-0927-z
60. Dale J, Stirling A, Zhang R, et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016;75:1043-50. doi: 10.1136/annrheumdis-2015-208941
61. Haavardsholm EA, Aga AB, Olsen IC, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016;354:i4205. doi: 10.1136/bmj.i4205
62. Caporali R, Smolen JS. Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. Ann Rheum Dis. 2018;77(1):18-20. doi: 10.1136/annrheumdis2017-211458
63. Simpson E, Hock E, Stevenson M, et al. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technol Assess. 2018;22(20):1-258. doi: 10.3310/hta22200
64. Burgers LE, Boeters DM, Reijnierse M, van der Helm-van Mil AHM. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study. Arthritis Res Ther. 2018 10;20(1):68. doi: 10.1186/s13075-018-1553-8
65. Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2(1):e000009. doi: 10.1136/rmdopen-2014-000
66. Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995- 4484-2017-277-294
67. Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun. 2017;83:95-112. doi: 10.1016/j.jaut.2017.07.003
68. Malmstrom V, Cartina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Rheumatol. 2017;13(2):79-86. doi: 10.1038/nrrheum.2016.200
69. Catrina AI, Svensson CI, Malmström V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol. 2017;13(2):79-86. doi: 10.1038/nrrheum.2016.200
70. Martin-Mola E, Balsa A, Garcia-Vicuna R, et al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36(8):1043-63. doi: 10.1007/s00296-016-3506-3
71. Авдеева АС, Кусевич ДА. Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(3):295-303 [Avdeeva AS, Kusevich DA. The role of laboratory biomarkers in predicting the efficiency of rituximab therapy for rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):295-303 (In Russ.)]. doi: 10.14412/1995-4484-2017-295-303
72. Насонов ЕЛ. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: A novel formulation, new mechanisms, new possibilities. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):522-41 (In Russ.)]. doi: 10.14412/1995-4484-2015-522-541
73. Figueiredo CP, Bang H, Cobra JF, et al. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis. 2017;76:399-407. doi: 10.1136/annrheumdis-2016-209297
74. De Moel EC, Derksen VFAM, Stoeken G, et al. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res Ther. 2018;20(1):33. doi: 10.1186/s13075-018-1520-4
75. Pelzek AJ, Gronwall C, Rosenthal P, et al. Disease associated anti-citrullinated protein memory B cells in rheumatoid arthritis persist in clinical remission. Arthritis Rheum. 2017;69:1176-86. doi: 10.1002/art.40053
76. Jansen DTSL, Emery P, Smolen JS, et al. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open. 2018 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564
77. Burgoyne CH, Field SL, Brown AK, et al. Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Ann Rheum Dis. 2008;67(6):750-7. doi: 10.1136/ard.2007.073833
78. Ponchel F, Goёb V, Parmar R, et al. An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis. 2014;73:2047-53. doi: 10.1136/annrheumdis-2013-203566
79. Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE. 2013;8:e60635. doi: 10.1371/journal.pone.0060635
80. Curtis JR, van der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012;64:1794-803. doi: 10.1002/acr.21767
81. Van der Helm-van Mil AH, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology. 2013;52:839- 46. doi: 10.1093/rheumatology/kes378
82. Markusse I, Dirven L, van den Broek M, et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatol. 2014;41:2114-9. doi: 10.3899/jrheum.131412
83. Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900
84. Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:760-70. doi: 10.3899/jrheum.140628
85. Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499- 505. doi: 10.1136/annrheumdis-2013-203923
86. Tweehuysen L, den Broeder N, van Herwaarden N, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654. doi: 10.1136/rmdopen-2018-000654
87. Kiely PD. Biologic efficacy optimization – a step towards personalized medicine. Rheumatology (Oxford). 2016;55(5):780-8. doi: 10.1093/rheumatology/kev356
88. Tweehuysen L, van den Ende CH, Beeren FM, et al. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis Rheum. 2017;69(2):301-8. doi: 10.1002/art.39946
89. Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018 Mar 27. doi: 10.1136/annrheumdis-2017-212862
90. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-89. doi: 10.1038/nrrheum.2015.8
91. De Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2017 Oct 4. doi: 10.1093/rheumatology/kex349
92. Kearsley-Fleet L, De Cock D, Watson K, et al. Refractory disease in rheumatoid arthritis: results from the british society of rheumatology biologics register for rheumatoid arthritis. Arthritis Rheum. 2017;69: Abstract Number 141.
93. Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology. 2016;55:210- 20. doi: 10.1093/rheumatology/kev277
94. Ranzolin A, Brenol JC, Bredemeier M, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:794-800. doi: 10.1002/art.24430
95. Lee YC, Frits ML, Iannaccone CK, et al. Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheum. 2014;66:2006-14. doi: 10.1002/art.38682
96. Haliloglu S, Carlioglu A, Akdeniz D, et al. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34:1275-80. doi: 10.1007/s00296-014-2972-8
97. Atzeni F, Cazzola M, Benucci M, et al. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol. 2011;25:165-71. doi: 10.1016/j.berh.2010.01.011
98. Mian AN, Chaabo K, Wajed J, et al. Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound. BMC Musculoskelet Disord. 2016;17:404. doi: 10.1186/s12891-016- 1258-6
99. Unger M, Alasti F, Supp G, et al. The good, the bad and the ugly – refractory rheumatoid arthritis in 2016. Arthritis Rheum. 2016;68(Suppl 10):Abstract No. 3015. Available from: http://acrabstracts.org/abstract/the-good-the-bad-and-the-uglyrefractory-rheumatoid-arthritis-in-2016/ (27 August 2017, date last accessed).
100. Orange DE, Agius P, DiCarlo EF, et al. Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data. Arthritis Rheum. 2018;70(5):690-701. doi: 10.1002/art.40428
101. Basu N, Kaplan CM, Ichesco E, et al. Neurobiological features of fibromyalgia are also present amond rheumatoid arthritis patients Arthritis Rheum. 2018 Feb 13. doi: 10.1002/art.40451
102. George M, Baker JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep. 2016;18:6. doi: 10.1007/s11926-015-0550-z
103. Pasma A, van Spijker A, Hazes JMW, et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43:18-28. doi: 10.1016/j.semarthrit.2012.12.001
104. Vlieland ND, Gardarsdottir H, Bouvy ML, et al. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology. 2016;55:704-9. doi: 10.1093/rheumatology/kev394
105. Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(2):207-14. doi: 10.1097/BOR.0000000000000470
106. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822-4. doi: 10.1038/nm.3260
107. McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis – shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63-8. doi: 10.1038/nrrheum.2015.171
108. Romao VC, Vital EM, Fonseca JE, et al. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19:1-13. doi: 10.1186/s13075-017-1445-3
109. Yu MB, Firek A, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. 2018 Mar 12. doi: 10.1007/s10787-018- 0459-z
110. Cuppen BV, Welsing PM, Sprengers JJ, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(5):826-39. doi: 10.1093/rheumatology/kev421
111. Maldonado-Montoro M, Canadas-Garre M, Gonzalez-Utrilla A, et al. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016;111:264- 71. doi: 10.1016/j.phrs.2016.06.016
Рецензия
Для цитирования:
Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. https://doi.org/10.14412/1995-4484-2018-263-271
For citation:
Nasonov E.L., Olyunin Yu.A., Lila A.M. RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE. Rheumatology Science and Practice. 2018;56(3):263-271. (In Russ.) https://doi.org/10.14412/1995-4484-2018-263-271
Просмотров:
4212
Послать статью по эл. почте 